Hereditary Cancer Testing
Knowing your patients’ genetics can provide answers to some of the most pressing questions about their cancer or potential risk of cancer.
Importance of Hereditary Cancer Testing
5-10% of all cancers are caused by an inherited genetic mutation. Your patients that have a genetic mutation, or hereditary cancer, can be far more likely to develop certain cancers and often at a much younger age. Patients with hereditary cancer may benefit from more frequent screening, surgical considerations, or treatment plans based on medical society guidelines. Patients may also qualify for certain targeted therapy options based on their mutation status.
Hereditary cancer testing can help determine your screening and treatment decisions.
Why Myriad myRisk?
You and your patients deserve accurate and actionable test results that you can trust. Myriad myRisk® delivers the greatest value through industry-leading accuracy, personalized service, and affordable testing.
Reduce False Negatives
Earlier Intervention
Save Time & Money
Important Myriad myRisk Features and Additions
Genes and Syndromes Included
What genes and syndromes does Myriad myRisk test for? Click below to view the gene table.
Myriad myRisk with RiskScore®
Myriad can also provide eligible patients with a riskScore, a breast cancer risk prediction tool which provides a 5-year and remaining lifetime risk of breast cancer by analyzing several personalized factors at no additional cost.
For certain women who receive a positive Myriad myRisk result in CHEK2, riskScore can provide a more comprehensive risk assessment by quantifying remaining lifetime risk, an industry first.
MyRisk STAT
For breast or pancreatic cancer patients that are surgery or treatment pending, myRisk STAT can give you faster results to help determine treatment eligibility and surgery decisions.
- BRCA 1/2, PALB2 and 8 other genes in 5-12 calendar days
- Full panel and report within 14 calendar days or less. No reflex needed!
Variant Reclassification
Myriad’s myVisionTM Variant Interpretation Program uses many methods to analyze, classify and reclassify gene variants. These methods include several proprietary and clinically validated tools.
In addition to offering the gold standard in variant classification at the time of testing, Myriad will provide you and your patients an updated result if a variant is reclassified, no matter when the original testing occurred.
RNA Analysis
Myriad uses RNA analysis to reduce the rate of variants of unknown significance and provide the most accurate answers for patients and healthcare providers. Since launching the RNA analysis program in 2015, thousands of patients have received updated results with 78% of reclassifications leading to changes in medical management guidelines.
Who is myRisk Intended For?
Myriad myRisk is intended for both men and women. If a patient has a personal or family history of certain cancers, hereditary cancer testing can determine whether an individual has a hereditary cancer risk of developing a future cancer.
Myriad myRisk can also determine whether a patient is appropriate for certain advanced cancer treatments like PARP Inhibitors.
Testing Process
1
Patient identification of individuals who meet guidelines for hereditary cancer testing
- myGeneHistory is our digital screening tool, designed so you can easily identify your patients that meet guidelines for hereditary cancer testing. Learn more about myGeneHistory here.
2
Fill out test request form
-
- An electronic test request form is available through our online portal, MyriadPro. Learn more about MyriadPro here.
- Download test request form here.
3
1
Collect Patient Sample
- Blood and saliva kits available – either collect sample in your practice or test kits can now be sent to your patients for at-home test – Learn more here.
4
1
You or your patient send sample to Myriad
5
1
Receive results in 7-14 days
- Receive results through MyriadPro, via mail, or both.
Understanding Myriad myRisk Results
Positive- A genetic mutation was found in 1 or more of the genes tested
- The patient is at increased risk for cancer
- A summary of medical management guidelines will be provided specific to the patient’s gene mutation(s)
Elevated- No genetic mutation was found in the genes tested
- The patient is at elevated risk for cancer based on an analysis of additional genetic markers, personal clinical risk factors, and/or their family’s history of cancer
- A summary of medical management guidelines will be provided based on the patient’s elevated risk
Negative- No genetic mutation was found in the genes tested
- The common causes of hereditary cancer have been ruled out, but depending on family history of cancer, increased risks could still remain
- Depending on their family history, medical management is usually based on general population screening guidelines; however, discussion with your patient can determine if there are any changes in medical management that are most appropriate for them
Variant of uncertain significance- A change in a gene has been identified
- It is not yet known if the change is associated with increased cancer risk
- Medical management based on personal and family history of cancer until more is understood about the specific change
Get Started
Find an Account Executive
Ship Kits to Patients
Myriad offers two different processes to ship the Myriad myRisk® or BRACAnalysis CDx® test kits directly to your patients’ homes.
